CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2015—EKF Diagnostics has entered a multiyear collaborative relationship with Joslin Diabetes Center in support of the ongoing clinical and commercial translation of tumor necrosis factor receptor 1 and 2 biomarkers. EKF will access certain clinical and research expertise at Joslin under the center’s corporate liaison program to further develop its TNFR biomarker test. Two objectives of this effort are to accelerate the clinical development of and understand physician adoption criteria and trends relating to the TNFR 1/2 test and advance the research to support the clinical utility of TNFR 1 and 2 assays as biomarkers in diabetic kidney disease.
EKF Diagnostics, +44 (0)29 20 710570